Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H100 Group ABFRA:GS9 35 EV-to-EBITDA is -104.78 as of Aug. 02, 2026. GuruFocus rates FRA:GS9 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 509 Healthcare Providers & Services companies, H100 Group AB ranks worse than 196463.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, H100 Group AB's enterprise value is €36.15 Mil.
H100 Group AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.35 Mil. Therefore, H100 Group AB's EV-to-EBITDA for today is -104.78.
The historical rank and industry rank for H100 Group AB's EV-to-EBITDA or its related term are showing as below:
FRA:GS9'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -119.51 Med: -1.33 Max: 76.97
Current: -105.1
During the past 8 years, the highest EV-to-EBITDA of H100 Group AB was 76.97. The lowest was -119.51. And the median was -1.33.
FRA:GS9's EV-to-EBITDA is ranked worse than 100% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 11.07
vs FRA:GS9: -105.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
H100 Group AB's PE Ratio (TTM) for today is calculated as:
H100 Group AB's share price for today is €0.081.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. H100 Group AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.016.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for H100 Group AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GS9 vs VEEV, BTSG, HQY: EV-to-EBITDA Comparison
For the Health Information Services subindustry, H100 Group AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H100 Group AB EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, H100 Group AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where H100 Group AB's EV-to-EBITDA falls into.
H100 Group AB's current Enterprise Value is €36.15 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. H100 Group AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H100 Group AB (FRA:GS9) has a EV-to-EBITDA of -104.78 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on H100 Group AB. According to the industry distribution chart, H100 Group AB ranks #999999 out of 509 companies in the Healthcare Providers & Services industry.
Is H100 Group AB's EV-to-EBITDA too high?
H100 Group AB's current EV-to-EBITDA is -104.78. Based on the distribution chart, H100 Group AB ranks #999999 out of 509 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, H100 Group AB has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does H100 Group AB's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, H100 Group AB ranks #999999 out of 509 companies for EV-to-EBITDA. This places H100 Group AB in the lower half of its industry. The industry median EV-to-EBITDA is 11.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.07, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on H100 Group AB. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H100 Group AB's current EV-to-EBITDA is -104.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H100 Group AB stock overvalued right now?
H100 Group AB (FRA:GS9) has a current EV-to-EBITDA of -104.78. The current EV-to-EBITDA is -104.78. H100 Group AB's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For H100 Group AB (FRA:GS9), the current EV-to-EBITDA is -104.78 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
H100 Group AB is a Swedish health technology company and the Bitcoin Treasury Company in the Nordics. The Company's objective is to maximize Bitcoin exposure per share by expanding its Bitcoin treasury through financial instruments. The Company operates through two business areas: Bitcoin Treasury operations, which focus on increasing Bitcoin exposure per share through strategic and financial instruments, and a health-tech division that supports health and longevity providers with AI-powered automation and growth tools. The Company generates revenue from digital services related to training and nutrition coaching provided to B2C customers and SaaS revenue related to the Group's digital platform provided to B2B customers. It operates in Sweden and Norway.
35GF Score
Get the complete analysis for FRA:GS9
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GS9 has been successfully added to your 
